Trial Profile
Clinical study of TA-650 in patients with ankylosing spondylitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 May 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 21 May 2016 New trial record